Takeda Pharmaceutical Company, Becoming a Global Company (A) Case Solution
In 2007, Takeda was a well known Japanese pharmaceutical company with sales mostly in Japan and the United States Although Takeda ranked around 15th in global sales, the pharmaceutical market had actually been moving as a result of significant market debt consolidation. Yasuchika Hasegawa, the president of Takeda, was worried about the future of the service provider. To counter the diminishing Japanese pharmaceutical market, Takeda had actually broadened its company to abroad markets. However Takeda's efforts to become a global company had actually been slammed as sluggish and not adequately aggressive. One factor for this was Takeda's risk-averse business culture. Worse, Takeda's R&D pipeline was diminishing, and patents on numerous of its significant items will end-- which would undoubtedly result in a decrease in revenues as generics went into the marketplace. This case checks out Hasegawa's strategy to change Takeda into a world-wide pharmaceutical company in a quickly altering market. It covers Takeda's background, market patterns, and Hasegawa's acquisition techniques.
This is just an excerpt. This case is about Business
Related Case Solutions & Analyses:
Negotiation Exercise on Tradeable Pollution Allowances: Group Utility 3
ACTC Customer Service Department
Montecito State College
Organizational Inclusion
Leica Camera: A “Boutique” Firm Faces a World of Change
Giordano International: Sustained Success Beyond 2005
Levi Strauss & Co. (C)
Silkor Laser Medical Center
A-CAT Corp.
Ajax Petroleum
